François Audenet1, John P Sfakianos1, Nikhil Waingankar1, Nora H Ruel2, Matthew D Galsky3, Bertram E Yuh4, Greg E Gin5. 1. Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY. 2. Division of Biostatistics, City of Hope National Medical Center, Duarte, CA. 3. Department of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY. 4. Division of Urology and Urologic Oncology, City of Hope National Medical Center, Duarte, CA. 5. Division of Urology, VA Long Beach Healthcare System, Long Beach, CA; Department of Urology, University of California, Irvine, Orange, CA. Electronic address: ggin1@uci.edu.
Abstract
OBJECTIVES: To investigate delays to neoadjuvant chemotherapy (NAC) and radical cystectomy (RC) and their effect on outcomes in a large national registry of patients with localized muscle invasive bladder cancer. PATIENTS AND METHODS: Within the National Cancer Database (2004-2014), we identified 2,227 patients who underwent NAC and RC for cT2-T4aN0M0 urothelial carcinoma of the bladder. Times from diagnosis to treatments were tested for association with overall survival and pathologic outcomes, using Cox models, and restricted cubic splines regression. RESULTS: Median times from diagnosis to NAC and RC were 39 days (interquartile range: 26-56) and 155 days (interquartile range: 131-185), respectively. Time to NAC and time to RC were not associated with overall survival in the complete cohort, as well as in subgroups of responders and nonresponders to NAC. Overall, 916 patients (41%) were upstaged after RC, including 485 patients (22%) with positive lymph nodes. We identified delay to NAC ≥8 weeks as a significant cut-off point to predict the risk of upstaging in multivariable analysis (odds ratio: 1.27; 95% confidence interval: 1.02-1.59; P = 0.031). Black race, Medicaid insurance, and academic facilities were associated with a higher risk of delayed treatment. CONCLUSION: After diagnosis of muscle invasive bladder cancer, NAC should be initiated as soon as possible and no more than 8 weeks to prevent upstaging. There is no evidence to support avoiding NAC due to concerns of delayed RC that was generated from surgery alone studies, as long as RC is performed within 7 months from initial diagnosis.
OBJECTIVES: To investigate delays to neoadjuvant chemotherapy (NAC) and radical cystectomy (RC) and their effect on outcomes in a large national registry of patients with localized muscle invasive bladder cancer. PATIENTS AND METHODS: Within the National Cancer Database (2004-2014), we identified 2,227 patients who underwent NAC and RC for cT2-T4aN0M0 urothelial carcinoma of the bladder. Times from diagnosis to treatments were tested for association with overall survival and pathologic outcomes, using Cox models, and restricted cubic splines regression. RESULTS: Median times from diagnosis to NAC and RC were 39 days (interquartile range: 26-56) and 155 days (interquartile range: 131-185), respectively. Time to NAC and time to RC were not associated with overall survival in the complete cohort, as well as in subgroups of responders and nonresponders to NAC. Overall, 916 patients (41%) were upstaged after RC, including 485 patients (22%) with positive lymph nodes. We identified delay to NAC ≥8 weeks as a significant cut-off point to predict the risk of upstaging in multivariable analysis (odds ratio: 1.27; 95% confidence interval: 1.02-1.59; P = 0.031). Black race, Medicaid insurance, and academic facilities were associated with a higher risk of delayed treatment. CONCLUSION: After diagnosis of muscle invasive bladder cancer, NAC should be initiated as soon as possible and no more than 8 weeks to prevent upstaging. There is no evidence to support avoiding NAC due to concerns of delayed RC that was generated from surgery alone studies, as long as RC is performed within 7 months from initial diagnosis.
Authors: Rashid K Sayyid; Diana Magee; Amanda E Hird; Benjamin T Harper; Eric Webb; Katherine L Fratino; Martha K Terris; Rabii Madi; Raj Satkunasivam; Christopher J D Wallis; Zachary Klaassen Journal: Can Urol Assoc J Date: 2021-01 Impact factor: 1.862
Authors: M Kanmalar; Siti Fairus Abdul Sani; Nur Izzahtul Nabilla B Kamri; Nur Akmarina B M Said; Amirah Hajirah B A Jamil; S Kuppusamy; K S Mun; D A Bradley Journal: Cell Mol Biol Lett Date: 2022-01-29 Impact factor: 5.787
Authors: Christopher J D Wallis; Giacomo Novara; Laura Marandino; Axel Bex; Ashish M Kamat; R Jeffrey Karnes; Todd M Morgan; Nicolas Mottet; Silke Gillessen; Alberto Bossi; Morgan Roupret; Thomas Powles; Andrea Necchi; James W F Catto; Zachary Klaassen Journal: Eur Urol Date: 2020-05-03 Impact factor: 20.096